Zobrazeno 1 - 10
of 164
pro vyhledávání: ''
Publikováno v:
Transplantation Proceedings. 53:1700-1706
Background Limited data are available on the use of oral antiviral therapy, particularly the long-term use of entecavir monotherapy in patients with hepatitis B virus (HBV)–related diseases after liver transplant (LT). Methods The clinical data on
Autor:
Nicolas Bouvier, Yannick Le Meur, Cyril Garrouste, Dominique Bertrand, Johnny Sayegh, Eloi Chevallier, Matthias Büchler, Sophie Caillard, Joseph Rivalan, Antoine Thierry, Lionel Rostaing, Philippe Gatault, Charlotte Colosio, Jean-Philippe Rerolle
Publikováno v:
Transplantation Proceedings
Transplantation Proceedings, 2020, 52 (10), pp.3179-3185. ⟨10.1016/j.transproceed.2020.06.005⟩
Transplantation Proceedings, 2020, 52 (10), pp.3179-3185. ⟨10.1016/j.transproceed.2020.06.005⟩
Kidney transplant recipients (KTRs) are frequently infected with chronic hepatitis C virus (HCV), which can increase the risk of graft loss. Active HCV infections among KTRs are associated with shorter survival times. The emergence of very efficient
Autor:
Chun Seong Ong, Wan Ahmad Hafiz Wan Md Adnan, Kok Peng Ng, Soo Kun Lim, Maisarah Jalalonmuhali, Yee Wan Lee
Publikováno v:
Transplantation Proceedings. 52:1709-1714
The aim of induction therapy in the management of kidney transplant is to reduce the incidence of acute rejection and delayed graft function after kidney transplant. The agent for induction therapy differs depending on the recipient risks. The regime
Autor:
Cláudio S. Melaragno, Adriano Miziara Gonzalez, Marcelo Moura Linhares, Erika B Rangel, Jose O. Medina-Pestana, Rubens Marcella-Neto, João Roberto de Sá, Alcides Augusto Salzedas-Neto
Publikováno v:
Transplantation Proceedings. 52:1376-1379
Background Pancreas transplant is an effective treatment for insulin-dependent diabetic individuals with end-stage renal disease, yet immunosuppression-associated adverse events may adversely affect patient and graft survival. The aim of the study wa
Publikováno v:
Transplantation Proceedings. 51:2602-2605
Background Rabbit antithymocyte globulin (rATG) induction is associated with reduction in the occurrence of de novo donor-specific antibody (DSA) and antibody-mediated rejection (AMR). Therefore, rATG administration is considered as a treatment for A
Autor:
Tomonori Nakazato, Shinji Ogura
Publikováno v:
Transplantation Proceedings. 53:405-407
Elevated plasma fibrinogen is associated with tumor progression and poor outcomes in several cancers. However, no studies have demonstrated the prognostic value of hyperfibrinogenemia in the setting of autologous hematopoietic stem cell transplantati
Autor:
Dimitrios S. Goumenos, E. Savvidaki, Theodoros Ntrinias, Marios Papasotiriou, Evangelos Papachristou
Publikováno v:
Transplantation proceedings. 53(9)
Dyslipidemia is common in kidney transplant recipients owing to the disturbance of lipid metabolism caused by chronic kidney disease and the effect of immunosuppression on lipid metabolism. Patients receiving treatment with mammalian target of rapamy
Autor:
J. de la Cruz Lombardo, S. López Ortega, R. González Grande, I. Santaella Leiva, M. Jiménez Pérez
Publikováno v:
Transplantation Proceedings. 52:540-542
Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is increasing, with a consequent impact on survival. Here we report our experience with sorafenib to treat HCC recurrence after LT. Patients and methods We undertook a retr
Autor:
Patricia Abellán Alfocea, Mercedes González Sánchez, Maria Dolores Espinosa Aguilar, Eduardo Redondo Cerezo, Flor Nogueras López, Eva Julissa Ortega Suazo, M. Angeles López Garrido
Publikováno v:
Transplantation Proceedings. 52:553-555
Background Calcineurin inhibitors are associated with the development of de novo tumors and increased recurrence of hepatocellular carcinoma after liver transplant. It has been suggested that mammalian target of rapamycin inhibitors (everolimus [EVR]
Publikováno v:
Transplantation proceedings. 53(5)
Posttransplant lymphoproliferative disorder (PTLD) occurs in 1% to 3% of adult renal transplant recipients (RTRs). PTLD has a heterogeneous presentation and is often associated with Epstein-Barr virus (EBV) and immunosuppression. We present a descrip